|
|
|||||||||
Basic Science Investigation |
1 Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 2 Department of Nephrology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; and 3 Department of Pharmacology and Toxicology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Correspondence: For correspondence or reprints contact: Julliëtte E.M. van Eerd, Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. E-mail: j.vaneerd{at}nucmed.umcn.nl
111In-Diethylenetriaminepentaacetic acid-octreotide generally is used for the scintigraphic imaging of neuroendocrine and other somatostatin receptorpositive tumors. On the basis of the successful targeting of octreotide, radiolabeled somatostatin analogs, such as 90Y-(1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid [DOTA])0-Tyr3-octreotide and 177Lu-DOTA0-Tyr3-octreotate, were developed for peptide receptor radionuclide therapy. However, the maximum tolerated doses of these analogs are limited because of the high and persistent renal uptake that leads to relatively high radiation doses in the kidneys. Renal uptake can be reduced by coinfusion of basic amino acids or polypeptides. However, high doses of basic amino acids can induce severe side effects. It was reported that the infusion of gelatin-based plasma expanders resulted in increased low-molecular-weight proteinuria, suggesting that these plasma expanders interfere with the tubular reabsorption of peptides and proteins. In the present study, we analyzed the effects of several plasma expanders on the renal uptake of 111In-octreotide in rats and mice. Methods: Wistar rats and BALB/c mice were injected with 0.5 or 0.1 mL of plasma expander, respectively. Thereafter, the animals received 111In-octreotide intravenously. Animals were killed at 20 h after the injection of the radiopharmaceutical. Organs were dissected, and the amount of radioactivity in the organs and tissues was measured. Results: The administration of 20 mg of Gelofusine in rats or 4 mg in mice was as effective in reducing the renal uptake of 111In-octreotide as the administration of 80 or 20 mg of lysine in rats or mice, respectively, without reducing 111In-octreotide uptake in receptor-positive organs. Plasma expanders based on starch or dextran had no effect on the renal uptake of 111In-octreotide. Conclusion: The gelatin-based plasma expander Gelofusine significantly reduced the kidney uptake of 111In-octreotide as effectively as did lysine. Because Gelofusine is a well-known and generally used blood volume substitute that can be applied safely without the induction of toxicity, evaluation of this compound for its potential to reduce the kidney uptake of radiolabeled peptides in patients is warranted.
Key Words: renal reabsorption plasma expander octreotide kidney
Related articles in JNM:
This article has been cited by other articles:
![]() |
G. Ren, Z. Liu, Z. Miao, H. Liu, M. Subbarayan, F. T. Chin, L. Zhang, S. S. Gambhir, and Z. Cheng PET of Malignant Melanoma Using 18F-Labeled Metallopeptides J. Nucl. Med., November 1, 2009; 50(11): 1865 - 1872. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Vegt, J. E.M. van Eerd, A. Eek, W. J.G. Oyen, J. F.M. Wetzels, M. de Jong, F. G.M. Russel, R. Masereeuw, M. Gotthardt, and O. C. Boerman Reducing Renal Uptake of Radiolabeled Peptides Using Albumin Fragments J. Nucl. Med., September 1, 2008; 49(9): 1506 - 1511. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Sharkey, H. Karacay, W. J. McBride, E. A. Rossi, C.-H. Chang, and D. M. Goldenberg Bispecific Antibody Pretargeting of Radionuclides for Immuno Single-Photon Emission Computed Tomography and Immuno Positron Emission Tomography Molecular Imaging: An Update Clin. Cancer Res., September 15, 2007; 13(18): 5577s - 5585s. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-b. Li, W. Cai, Q. Cao, K. Chen, Z. Wu, L. He, and X. Chen 64Cu-Labeled Tetrameric and Octameric RGD Peptides for Small-Animal PET of Tumor {alpha}v{beta}3 Integrin Expression J. Nucl. Med., July 1, 2007; 48(7): 1162 - 1171. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gotthardt, J. van Eerd-Vismale, W. J.G. Oyen, M. de Jong, H. Zhang, E. Rolleman, H. R. Maecke, M. Behe, and O. Boerman Indication for Different Mechanisms of Kidney Uptake of Radiolabeled Peptides J. Nucl. Med., April 1, 2007; 48(4): 596 - 601. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Orlova, V. Tolmachev, R. Pehrson, M. Lindborg, T. Tran, M. Sandstrom, F. Y. Nilsson, A. Wennborg, L. Abrahmsen, and J. Feldwisch Synthetic Affibody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors Cancer Res., March 1, 2007; 67(5): 2178 - 2186. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Rolleman, M. de Jong, R. Valkema, D. Kwekkeboom, B. Kam, and E. P. Krenning Inhibition of Kidney Uptake of Radiolabeled Somatostatin Analogs: Amino Acids or Gelofusine? J. Nucl. Med., October 1, 2006; 47(10): 1730 - 1731. [Full Text] [PDF] |
||||
![]() |
J. E.M. van Eerd, E. Vegt, J. F.M. Wetzels, F. G.M. Russel, R. Masereeuw, F. H.M. Corstens, O. C. Boerman, and W. J.G. Oyen Reply: Inhibition of Kidney Uptake of Radiolabeled Somatostatin Analogs: Amino Acids or Gelofusine? J. Nucl. Med., October 1, 2006; 47(10): 1731 - 1731. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |